Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells

Abstract

Aim: The Cluster of differentiation 44 (CD44) transmembrane protein is cleaved by γ-secretase, the inhibition of which blocks CD44 cleavage. This study aimed to determine the biological consequence of CD44 cleavage and its potential interaction with Runt-related transcription factor (RUNX2) in a sequence-specific manner in PC3 prostate cancer cells.

Methods: Using full-length and C-terminal deletion constructs of CD44-ICD (D1-D5) expressed as stable green fluorescent protein-fusion proteins in PC3 cells, we located possible RUNX2-binding sequences.

Results: Chromatin immunoprecipitation assays demonstrated that the C-terminal amino acid residues between amino acids 671 and 706 in D1 to D3 constructs were indispensable for sequence-specific binding of RUNX2. This binding was minimal for sequences in the D4 and D5 constructs. Correspondingly, an increase in matrix metalloprotease-9 (MMP-9) expression was observed at the mRNA and protein levels in PC3 cells stably expressing D1–D3 constructs.

Conclusion: These results provide biochemical evidence for the possible sequence-specific CD44-ICD/RUNX2 interaction and its functional relationship to MMP-9 transcription in the promoter region.

Keywords

Prostate cancer / metastasis / CD44 / RUNX2 / CD44-ICD / MMP-9 / tumorigenesis

References

[1] Siegel RL,Jemal A.Cancer statistics, 2019..CA Cancer J Clin2019;69:7-34

[2] Brawley OW.Prostate cancer epidemiology in the United States..World J Urol2012;30:195-200

[3] Adesunloye BA,Dahut WL.Marone G.Angiogenesis inhibitors in the treatment of prostate cancer..Angiogenesis, Lymphangiogenesis and Clinical Implications.2013;BaselS. KARGER AG197-215

[4] Varenhorst E,Berglund A,Sandblom G.Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases..Cancer Med2016;5:407-14 PMCID:PMC4799954

[5] Frieling JS,Lynch CC.Current and emerging therapies for bone metastatic castration-resistant prostate cancer..Cancer Control2015;22:109-20 PMCID:PMC4673894

[6] Desai B,Chellaiah MA.Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells..Mol Cancer2007;6:18 PMCID:PMC1828067

[7] Cooper CR,Pienta KJ.The role of alpha(v)beta(3) in prostate cancer progression..Neoplasia2002;4:191-4 PMCID:PMC1531692

[8] Weber GF.Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers..Brain Res Bull2000;53:421-4

[9] Naor D,Zahalka M,Holzmann B.Holzmann B.Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination..Leukocyte integrins in the immune system and malignant disease.1998;BerlinSpringer Berlin Heidelberg143-66

[10] Sy MS,Stamenkovic I.Distinct effects of two CD44 isoforms on tumor growth in vivo..J Exp Med1991;174:859-66 PMCID:PMC2118964

[11] Goodison S,Tarin D.CD44 cell adhesion molecules..Mol Pathol1999;52:189-96 PMCID:PMC395698

[12] Weber GF,Glimcher MJ.Receptor-ligand interaction between CD44 and osteopontin (Eta-1)..Science1996;271:509-12

[13] Desai B,Chellaiah MA.Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion..J Biol Chem2008;283:13856-66 PMCID:PMC2376228

[14] Chellaiah MA,Biswas R,Strauss-Schoenberger J.Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression..Mol Biol Cell2003;14:173-89 PMCID:PMC140236

[15] Desai B,Zhu J.Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface..J Cell Biochem2009;108:272-84 PMCID:PMC7198262

[16] Gupta A,Chellaiah MA.Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis..Mol Cancer2012;11:66 PMCID:PMC3499378

[17] Srinivasan D,Majumdar S,Chellaiah MA.Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2..J Cell Biochem2018;2413-28 PMCID:PMC6411465

[18] Murakami D,Nagano O,Tomita T.Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44..Oncogene2003;22:1511-6

[19] Okamoto I,Murakami D,Araki N.Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway..J Cell Biol2001;155:755-62 PMCID:PMC2150876

[20] Okamoto I,Tsuiki H,Nakao M.CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration..Oncogene1999;18:1435-46

[21] Miletti-González KE,Kumaran MN,Wernyj RP.Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element..J Biol Chem2012;287:18995-9007 PMCID:PMC3365933

[22] Senbanjo LT,Majumdar S.Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells..Cell Commun Signal2019;17:80 PMCID:PMC6647163

[23] van der Deen M,Wang T,Altieri DC.The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells..J Cell Biochem2010;109:828-37 PMCID:PMC2925394

[24] Zhang X,Dobson JR,Hong D.Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1..J Cell Biochem2015;116:2098-108 PMCID:PMC4515199

[25] Pratap J,Stein GS.Metastatic bone disease: role of transcription factors and future targets..Bone2011;48:30-6 PMCID:PMC2958222

[26] Akech J,Bedard K,Hussain S.Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions..Oncogene2010;29:811-21 PMCID:PMC2820596

[27] Chua CW,Yuen HF,Man K.Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform..Clin Cancer Res2009;15:4322-35

[28] Park JS,Oh HJ,Lim MA.Grape-seed proanthocyanidin extract as suppressors of bone destruction in inflammatory autoimmune arthritis..PLoS One2012;7:e51377 PMCID:PMC3519627

[29] Neumann C,Paulsen F,Birke MT.Osteopontin is induced by TGF-β2 and regulates metabolic cell activity in cultured human optic nerve head astrocytes..PLoS One2014;9:e92762 PMCID:PMC3981660

[30] Chellaiah M.Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase..Mol Biol Cell1996;7:743-53 PMCID:PMC275927

[31] Chellaiah M,Alvarez U.c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase..J Biol Chem1998;273:11908-16

[32] Schneider A,Gutkind JS.Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma..Neoplasia2008;10:1295-302 PMCID:PMC2570606

[33] Cho Y,Kang HG,Kim SJ.Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer..Oncotarget2015;6:8709-21 PMCID:PMC4496178

[34] Cichy J.The liberation of CD44..J Cell Biol2003;161:839-43 PMCID:PMC2172964

[35] Okamoto I,Kenyon LC,Emlet DR.Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors..Am J Pathol2002;160:441-7 PMCID:PMC1850643

[36] Liu X.Stimulation of type IV collagenase expression by linoleic acid in a metastatic human breast cancer cell line..Cancer Letters1994;76:71-7

[37] Masson D,Denis M,Loirat MJ.Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer..Br J Cancer1999;80:1995-2000 PMCID:PMC2363139

[38] Gupta A,Sadashivaiah K,Schneider A.Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9..ScientificWorldJournal2013;2013:493689 PMCID:PMC3580924

[39] Pratap J,Javed A,van Wijnen AJ.Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone..Cancer Metastasis Rev2006;25:589-600

[40] Pratap J,Languino LR,Stein JL.The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion..Mol Cell Biol2005;25:8581-91 PMCID:PMC1265732